Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

ment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during tre
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014 Integrity Applications, ... of the GlucoTrack ® model DF-F noninvasive ... has entered, through its wholly-owned subsidiary, Integrity Applications ... the manufacturing arm of Acer Inc.  Pursuant to ... service (on a non-exclusive basis) the GlucoTrack Model ...
(Date:7/21/2014)... Calif. , July 21, 2014   ... a biopharmaceutical company leading the discovery and development ... the U.S. Food & Drug Administration (FDA) has ... stranded, chemically modified oligonucleotide that binds to and ... therapeutic for the treatment of Alport syndrome, a ...
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
... a clinico-molecular informatics company, today announced the commercialization ... lines that translate patient-specific molecular and genomic data, ... more effective drug choices for patients. ... drastically and clinical data becoming increasingly accessible, today,s ...
... /PR Newswire-Asia/ -- Global Pharm Holdings Group, Inc. ... growing vertically integrated pharmaceutical company engaged in the ... processing, and herbal cultivation and sales in China ... Shandong provinces, today announced the appointment of Mr. ...
Cached Medicine Technology:MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:7/22/2014)... Bar, CA (PRWEB) July 22, 2014 ... leading provider of enterprise Time and Attendance / ... in Iowa, a NOVAtime 3000 customer since 2007, ... self-hosted, licensed version of NOVAtime’s state-of-the-art, web-based time ... Lutheran Services in Iowa (LSI) is a human ...
(Date:7/22/2014)... Orem, UT (PRWEB) July 22, 2014 Most people ... first is a weak appetite and the second is a fast ... CB-1 Weight Gainer provides ways to help fight these ... lack of appetite. There are people out there who just can’t ... take bites and then they are full. The cause of this ...
(Date:7/21/2014)... designed to target and kill cancer cells could boost ... and help avoid amputation, a new study reports. , ... the effectiveness of a genetically engineered version of the ... use of the virus alongside isolated limb perfusion chemotherapy ... arm or leg as an alternative to amputation ...
(Date:7/21/2014)... July 22, 2014 iFitDress.com, a famous ... women, has announced its exclusive collection of 2014 ... a promotion for its brand new gowns. , iFitDress.com ... the current market. Its sales boomed in the recent ... products, but also because of the amicable services offered ...
(Date:7/21/2014)... July 21, 2014 The League of ... 1199SEIU United Healthcare Workers East (“1199SEIU”) today announced a ... issues facing healthcare providers and their employees. , ... require ratification by League and 1199SEIU members, employee wages ... addition, all existing worker benefits, including healthcare coverage with ...
Breaking Medicine News(10 mins):Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2Health News:League of Voluntary Hospitals and Homes and 1199SEIU Reach New Four-Year Collective Bargaining Agreement 2Health News:League of Voluntary Hospitals and Homes and 1199SEIU Reach New Four-Year Collective Bargaining Agreement 3
... 11 (HealthDay News) -- Low oxygen supply (hypoxia) increases the ... a severe traumatic brain injury (TBI), a new study finds. ... with TBI, most of whom had bleeding within the brain ... fared poorly, suffering severe disability, dying or being in a ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... demonstrated that cryoplasty post-dilitation compared to conventional balloon ... the risk of in-stent restenosis (ISR). Results from ... the 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific ...
... FRIDAY, Nov. 11 (HealthDay News) -- Repeated bouts of ... pain and infertility, a new study says. Pelvic inflammatory ... is marked by inflammation of the reproductive organs. The condition ... year and one in 10 of them becomes infertile, according ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... de novo coronary artery lesions showed a significantly ... to paclitaxel-eluting stents with permanent polymers. ... at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... the past 100 years, the Haber-Bosch process has been used ... the manufacture of fertilizer. Despite the longstanding reliability of the ... works. But now a team of chemists, led by Patrick ... how the ammonia is formed. Their findings are published in ...
... FRIDAY, Nov. 11 (HealthDay News) -- Age-related declines in ... to a new study. "The more income and ... be," co-author Virginia Richardson, a professor of social work ... release. The researchers analyzed data from roughly 6,500 ...
Cached Medicine News:Health News:Results of the COBRA trial reported at TCT 2011 2Health News:STD Complication May Double Infertility Risk 2Health News:Results of the NEXT clinical trial Reported at TCT 2011 2Health News:Researchers gain insight into 100-year-old Haber-Bbosch process 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: